|
|
|
|
31 * !
|
Mon, 8/3/2020,
10:00 AM -
11:50 AM
|
Virtual
|
|
Combination Therapy Dose-Finding in Oncology Drug Development — Topic Contributed Papers
|
|
Biopharmaceutical Section, Section on Bayesian Statistical Science, International Chinese Statistical Association
|
|
Organizer(s): Rong Liu, BMS
|
|
Chair(s): Olga Marchenko, Bayer
|
|
10:05 AM
|
Comparative Review of Phase I Dose-Finding Designs for Drug Combination Trials
Heng Zhou, Merck; Ruitao LIN, The University of Texas MD Anderson Cancer Center
|
|
10:25 AM
|
Dual-Agent Drug-Combination Designs for Finding Multiple Maximum Tolerated Dose Combinations in Oncology Phase I Trials
Xin Yang, Novartis
|
|
10:45 AM
|
Industry Experience on Combination Therapy Dose-Finding in Oncology Drug Development
Rong Liu, BMS
|
|
11:05 AM
|
Emerging Approaches in Combination Phase I Trials: Utilization of Historical Data and the Need to Consider Model Guided Designs and Endpoints Other Than DLTs
Suman Sen, Novartis Pharmaceuticals Corp
|
|
11:25 AM
|
Discussant: Cindy Gao, FDA
|
|
11:45 AM
|
Floor Discussion
|
